| pubmed-article:10325259 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C0733758 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C0014912 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C1705165 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C0883157 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C0971174 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C2700061 | lld:lifeskim |
| pubmed-article:10325259 | lifeskim:mentions | umls-concept:C1542147 | lld:lifeskim |
| pubmed-article:10325259 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10325259 | pubmed:dateCreated | 1999-7-14 | lld:pubmed |
| pubmed-article:10325259 | pubmed:abstractText | The roles of oestradiol, inhibin A and inhibin B in the luteal-follicular transition were assessed by means of specific assays. Six premenopausal women were studied during a control and then a cycle treated with percutaneous oestradiol 0.1 mg/day from day 10 after the luteinizing hormone (LH) surge until day 4 of the following cycle. Inhibin A concentrations decreased similarly in control and treated cycles from day -5 to day 2, then increased in control cycle to 23.3 +/- 3.4 pg/ml on day 10 (mean +/- SEM). They remained low until day 5 in treated cycles and were lower than controls on day 10 (P < 0.01). Follicle stimulating hormone (FSH) concentrations increased on day 1 in controls and on day 5 in treated cycles when oestradiol concentration fell abruptly. Inhibin B concentrations remained low until day 1 in controls and day 4 in treated cycles. In both, inhibin B concentrations increased 1 day after FSH, peaking at 160 pg/ml. FSH concentrations began to plateau when inhibin B concentrations were >100 pg/ml and oestradiol concentrations below 200 pmol/l. These data suggest that inhibin A is not responsible for FSH suppression in the luteal phase and that the negative control of FSH shifts from oestradiol in the luteal phase to inhibin B in the mid-follicular phase. | lld:pubmed |
| pubmed-article:10325259 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10325259 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10325259 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10325259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10325259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10325259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10325259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10325259 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10325259 | pubmed:month | May | lld:pubmed |
| pubmed-article:10325259 | pubmed:issn | 0268-1161 | lld:pubmed |
| pubmed-article:10325259 | pubmed:author | pubmed-author:RogerMM | lld:pubmed |
| pubmed-article:10325259 | pubmed:author | pubmed-author:BouchardPP | lld:pubmed |
| pubmed-article:10325259 | pubmed:author | pubmed-author:Christin-Mait... | lld:pubmed |
| pubmed-article:10325259 | pubmed:author | pubmed-author:LahlouNN | lld:pubmed |
| pubmed-article:10325259 | pubmed:author | pubmed-author:Le NestourEE | lld:pubmed |
| pubmed-article:10325259 | pubmed:author | pubmed-author:Chabbert-Buff... | lld:pubmed |
| pubmed-article:10325259 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10325259 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:10325259 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10325259 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10325259 | pubmed:pagination | 1190-3 | lld:pubmed |
| pubmed-article:10325259 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:meshHeading | pubmed-meshheading:10325259... | lld:pubmed |
| pubmed-article:10325259 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10325259 | pubmed:articleTitle | Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: inhibin A, oestradiol, or inhibin B? | lld:pubmed |
| pubmed-article:10325259 | pubmed:affiliation | INSERM U 342, Hôpital Saint-Vincent-de-Paul,82 av Denfert-Rochereau, 75014 Paris, France. | lld:pubmed |
| pubmed-article:10325259 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10325259 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10325259 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10325259 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:10325259 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10325259 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10325259 | lld:pubmed |
